AstraZeneca discontinued a late-stage trial of experimental drug volrustomig plus chemotherapy in metastatic non-small cell lung cancer after an independent committee found it unlikely to meet primary endpoints. The setback adds to recent pipeline scrutiny, though other volrustomig trials continue.
AstraZeneca halts lung cancer trial for volrustomig
Source: Reuters